Wagner Parra-Paladines

Oncología Médica. Hospital 12 de Octubre. Madrid

[The Lancet Oncology @TheLancetOncol]

🚨Online today: Chemotherapy +/- pembro followed by maintenance pembro +/- olaparib as first-line treatment in advanced BRCA non-mutated epithelial ovarian cancer: a phase 3 trial

From the ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators

Read here: https://t.co/vgLua3ZHMR

[Wagner Parra-Paladines @WagnerParra2]

@AinhoaMada @myESMO @H12Octubre Muchas felicidades Ainhoa, te mereces lo mejor y mucho más.

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 NEST | Phase II | Localized colon cancer

💉 Neoadjuvant botensilimab + balstilimab

🎯 Major pathologic response
🟠 pMMR: 41%
🟢 dMMR: 100%

✅ No surgical delays
🔥 Immune TME remodeling

💡 Encouraging activity, notably in pMMR disease.

🔗 https://t.co/iYGga9y97m

@OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🇨🇳 🧬 TALENTOP | Phase III | Locally advanced HCC

After response/stability to atezo + bev:
🔪 Surgery + adjuvant atezo/bev vs maintenance

⏳ TTF 20.4 vs 11.8 mo | HR 0.60
⚠️ G3–4 TRAEs 39% vs 21%

💡 Resection improved TTF in selected responders.

🔗 https://t.co/yL1W40tzTy

@OncoAlert

[Arndt Vogel @ArndtVogel]

ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer
@Annals_Oncology
https://t.co/YzKDr6M392
👉pan-RAS(ON) inhibitor daraxonrasib included in second-line therapy
@myESMO

[Ashish Singh @todrashish]

Simple biomarker for better patient selection in the clinic? @LizzySmyth1 @KoheiShitara @ajoyojohn @jtgeorgy @drmpk91

[Erman Akkus @Erman_Akkus]

🔵PDL-1 (CPS) in gastroesophageal cancers
🔬FDA and NCCN

#cancer #oncology #MedX #GI @OncoAlert

[Kohei shitara @KoheiShitara]

Pleased to share the design of the phase 3 LUCERNA trial of zolbetuximab + pembrolizumab + chemotherapy in CLDN18.2+, HER2-, PD-L1+ gastric/GEJ cancer. Enrollment is nearly complete. Looking forward to the results! @myESMO @OncoAlert https://t.co/0YI1wKLNxK

[Rohit Malde @roxboxfix]

Capecitabine + Oxaliplatin
Chemo Regimen

COLORECTAL cancers

Doses
Indications
Toxicity and Grading
Dose Reductions and Stopping Rules

A simple Glance for Oncologists in Clinics

[Erman Akkus @Erman_Akkus]

🏥TNT strategies in rectal cancer

#cancer #oncology #MedX @OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🇨🇳 RTChT vs ChT after D2 gastrectomy

📊 Phase III trial (n=620)

T4/N+ GC after D2 R0 resection

➕ Adj SOX + RT
❌ No DFS benefit
❌ No OS benefit

📈 5-y OS: 73.7% vs 71.4%

🎯 Routine adj RTChT after D2 gastrectomy remains unsupported.

🔗 https://t.co/oU65fsAW82

@OncoAlert

[MV Chandrakanth @ChandrakanthMv]

Can postoperative chemotherapy be omitted in PD-L1–positive resectable gastric cancer?

ASTRUM-006 suggests the answer may be yes.

In patients with PD-L1 CPS ≥5 gastric/GEJ adenocarcinoma, perioperative serplulimab + SOX followed by adjuvant serplulimab (without postoperative chemotherapy) improved EFS compared with standard perioperative SOX.

Key findings:

• CPS ≥10: EFS HR 0.65
• CPS ≥5: EFS HR 0.73
• 2-year EFS: 70% vs 54%
• Grade ≥3 toxicity: 47% vs 59%

A biomarker-selected, chemotherapy-sparing strategy delivered better outcomes with less toxicity.

The most intriguing question:
Is the benefit driven by PD-L1 selection, serplulimab, or elimination of postoperative chemotherapy?

#ASTRUM006 #ASCO2026 #GastricCancer #GIOncology #Immunotherapy #PDL1 #Oncology #MVOnco

[Dr Rishabh Jain @DrRishabhOnco]

What do you do when a patient with metastatic nasopharyngeal carcinoma has already failed chemotherapy and immunotherapy? 🤔

Options are limited.
Outcomes are poor.

The phase IIb MAGIC-M001 trial suggests an EGFR-ADC may offer a new path. 🧬

🔹 Becotatug vedotin
vs
🔸 Capecitabine or docetaxel

Study population:
📌 Recurrent/metastatic NPC
📌 Prior PD-1/PD-L1 inhibitor exposure
📌 ≥2 prior lines of systemic therapy
📌 ECOG 0-1

Results:

🎯 ORR
30.2% vs 11.5%
P=0.003

⏳ Median PFS
5.82 vs 2.83 months
HR 0.63

📉 37% lower risk of progression or death

❤️ Median OS
17.1 vs 12.0 months
HR 0.73
(Not statistically significant yet)

🩸 Grade ≥3 TRAEs
45.3% vs 50.6%

💡 Clinical takeaway:
For heavily pretreated, immunotherapy-exposed NPC, becotatug vedotin delivered meaningful improvements in response rate and PFS with manageable toxicity.

ADCs are rapidly reshaping the treatment landscape across solid tumors, and NPC may be next. 🚀

Full paper in comment.

@OncoAlert @myESMO @ASCO

#Oncology #NPC #HeadAndNeckCancer #ADC

[Katy Beckermann @katy_beckermann]

PTEN loss is associated with worse outcomes in prostate cancer. Now there's a way to act on it in the hormone-sensitive setting.

🎯 CAPItello-281: capivasertib + abiraterone improved rPFS in PTEN-deficient mHSPC, 33.2 vs 25.7 mo, HR 0.81. FDA approved this month, PTEN by IHC.

⚠️ The AKT inhibitor adds hyperglycemia, diarrhea, and rash, including grade 3 rash.

🏥 Plan for it: check glucose at baseline and on treatment with metformin ready, antihistamine prophylaxis for rash, loperamide early for diarrhea (onset around day 9).

Why this matters for your practice: 💡 The supportive care and counseling need to be set up early before the first dose.

What are you recommendations for handling glucose and skin monitoring for these patients? 🩺

👉CAPItello-281 full results: https://t.co/FRpQO9hmJO
#ProstateCancer #GUOnc

[S.Enf.Infecciosas HRUM @infeccHRUmalaga]

En #InternJInfectDis ENS. CLÍNICO #ITUcomplicada (📸👇🏻)donde #meropenem 7 días🆚Meropenem 3 días ➕ #FosfoTrometamol día 4 y 6 en #Enterobacterales R CFP 3 Gen.👉🏻 MISMA curación clínica👌🏻y ➖estancia🏥📉
Opción para #DESESCALAR🪜💊y #AhorroCarbapenemes
🔗🆓https://t.co/WOZMC22sLQ

[Angela Lamarca @DrAngelaLamarca]

🗞️Here it is, our latest paper on #adjuvant treatment in #BiliaryMalignancies

😬Improvement is much needed
🧐Will #IO be the answer?
🧐Shall we move to #neoadjuvant?

https://t.co/yIgxn9sCn7

@Alex_MedOnc @Hospital_FJD

[Annals of Oncology @Annals_Oncology]

🆕The addition of carboplatin to (neo)adjuvant chemotherapy (i.e., doxorubicin and cyclophosphamide followed by taxane) significantly ⬆️ event-free survival in patients with early TNBC
https://t.co/UGJo0sh930

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 Staging laparoscopy post-CT (n=128)

📈 Peritoneal disease resolution: 37%
📈 mOS: 53.7 vs 21.5 mo
📉 New Peritoneal disease: 5.6%

⚠️ Persistent Peritoneal disease = adverse prog factor
⚠️ Lim: false-neg findings

🎯 Best tool for selecting pts w/ fav peritoneal response

🔗 https://t.co/L9mAH15gt2
@OncoAlert @GrupoTTD

[Ainhoa Madariaga @AinhoaMada]

Happy to share our @AACR Cancer review of #ADCs in #GynecologicCancers #gyncsm
📍From approved ADCs to those on development
❗Resistance & sequencing
⏩ Toxicity management

Free access 👇 https://t.co/UPKQ2c0Rtw

@ArantzazuBarqu1
@LKasherman @StephanieLheur5 @OncoAlert

[Erman Akkus @Erman_Akkus]

🟡Transforming perioperative treatment of gastro-oesophageal adenocarcinoma

✅state-of-the-art perioperative management

👉https://t.co/ol258Y3kaR

#cancer #oncology #MedX #gastric @LizzySmyth1 @KoheiShitara @DrHongchengZhu @YJanjigianMD